Medicare Enrolled
Dr. Erin Chamberlain, M.D.
Hematology & Oncology · San Luis Obispo, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Chamberlain from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chamberlain?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chamberlain
Dr. Erin Chamberlain is a hematology & oncology specialist in San Luis Obispo, CA, with 12 years of NPI registration. Based on federal Medicare data, Dr. Chamberlain performed 113,955 Medicare services across 2,660 unique beneficiaries.
Between the years covered by Open Payments, Dr. Chamberlain received a total of $916 from 18 pharmaceutical and/or device companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chamberlain is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 12 years in practice
▲ Top 6% volume in CA
$916 industry payments
Medicare Practice Summary
Medicare Utilization ↗113,955
Medicare services
Top 6% in CA for hematology & oncology
2,660
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~9,496 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 23,600 | $43 | $213 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
15,810 | $0 | $10 |
| Paclitaxel chemotherapy injection | 13,677 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
12,600 | $0 | $10 |
| Denosumab injection (Prolia/Xgeva) | 8,400 | $18 | $90 |
| Injection, docetaxel, 1 mg | 7,098 | $1 | $73 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
5,700 | $2 | $20 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
5,580 | $38 | $194 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,710 | $1 | $95 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,228 | $0 | $5 |
| Bevacizumab-bvzr biosimilar injection, 10 mg An injection of bevacizumab-bvzr, a biosimilar medication, administered in a 10 mg dose. |
1,890 | $23 | $174 |
| Anti-nausea injection (ondansetron/Zofran) | 1,824 | $0 | $10 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
1,780 | $23 | $222 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
1,334 | $79 | $1,587 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
979 | $13 | $245 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 872 | $3 | $670 |
| Injection, leucovorin calcium, per 50 mg | 855 | $3 | $20 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
752 | $1 | $10 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
724 | $2 | $254 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
695 | $113 | $1,044 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
615 | $102 | $858 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
478 | $8 | $58 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
432 | $2 | $16 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
414 | $12 | $118 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
312 | $66 | $508 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
292 | $143 | $960 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
219 | $64 | $433 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
218 | $56 | $620 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
177 | $1 | $10 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
160 | $25 | $550 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
159 | $8 | $25 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 154 | $131 | $4,038 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
151 | $7 | $487 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
132 | $1 | $15 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
123 | $25 | $475 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
107 | $55 | $378 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
102 | $27 | $264 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
98 | $20 | $179 |
| 5% dextrose/water (500 ml = 1 unit) | 86 | $1 | $15 |
| New patient office visit, complex (60-74 min) | 80 | $170 | $1,360 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
48 | $2 | $25 |
| Prolonged intravenous chemotherapy administration This procedure involves the administration of chemotherapy medication directly into a vein over an extended period. |
43 | $109 | $1,163 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
42 | $1 | $13 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
39 | $11 | $225 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
39 | $49 | $449 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
30 | $17 | $99 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
28 | $82 | $864 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
22 | $108 | $1,085 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
17 | $27 | $135 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
16 | $98 | $680 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
14 | $27 | $294 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
15.7% high complexity
82.2% medium
2.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$916
Total received (2018-2024)
Avg $153/year across 6 years
Bottom 33% in CA for hematology & oncology
18
Companies
54
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$867 (94.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$49 (5.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$100
2023
$49
2022
$75
2020
$13
2019
$255
2018
$424
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Merck Sharp & Dohme LLC
$37
E.R. Squibb & Sons, L.L.C.
$25
Medtronic, Inc.
$22
PFIZER INC.
$16
Top 3 companies account for 83.6% of 2024 payments
All-time payments by company (2018-2024) ›
Merck Sharp & Dohme Corporation
$162
PFIZER INC.
$103
AstraZeneca Pharmaceuticals LP
$85
Medtronic, Inc.
$84
Astellas Pharma US Inc
$74
Novartis Pharmaceuticals Corporation
$64
Boehringer Ingelheim Pharmaceuticals, Inc.
$51
E.R. Squibb & Sons, L.L.C.
$42
Amgen Inc.
$40
Genentech USA, Inc.
$40
Merck Sharp & Dohme LLC
$37
Takeda Pharmaceuticals U.S.A., Inc.
$33
Seattle Genetics, Inc.
$30
Ipsen Biopharmaceuticals, Inc
$16
Spectrum Pharmaceuticals Inc.
$15
CSL Behring
$15
ABBVIE INC.
$13
Jazz Pharmaceuticals Inc.
$12
Top 3 companies account for 38.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Avastin · BOSULIF · CAMZYOS · EMEND · FASLODEX · Folotyn · GILOTRIF · IBRANCE · ICLUSIG · IMFINZI · INLYTA · INTELLIS ADAPTIVESTIM · KEYTRUDA · LYNPARZA · MYLOTARG · NOXAFIL · Neulasta · OPDIVO · Onivyde · PREVYMIS · SYNCHROMEDII · TASIGNA · VENCLEXTA · VYXEOS · XOSPATA · XTANDI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
9
Per 100K population
3.2
County median income
$93,398
Nearest hospital
FRENCH HOSPITAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Chamberlain is a mixed practice specialist, with above-average Medicare volume (top 6% in CA), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Chamberlain experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Chamberlain performed 23,600 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chamberlain receive payments from pharmaceutical companies?
Yes. Dr. Chamberlain received a total of $916 from 18 companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chamberlain's costs compare to other hematology & oncology specialists in San Luis Obispo?
Dr. Chamberlain's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chamberlain) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in San Luis Obispo
Browse hematology & oncology specialists in San Luis Obispo ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology